Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07446387) titled 'A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Jiangsu Cancer Institute & Hospital
Condition:
Metastatic Colorectal Cancer (CRC)
Intervention:
Drug: Iparomlimab and tuvonralimab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: February 1, 2026
Target...